Dashboard
Manage Tickers

RLAYRelay Therapeutics, Inc.

Nasdaq relaytx.com


$ 6.79 $ 0.03 (0.44 %)    

Friday, 30-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 6.79
$ 6.79 x 400
-- x --
-- - --
$ 5.70 - $ 12.14
1,166,834
na
909.11M
$ 1.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-27-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-overweight-on-relay-therapeutics-lowers-price-target-to-23
JP Morgan Maintains Overweight on Relay Th...
08/07/2024 18:18:47

JP Morgan analyst Eric Joseph maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and lowers the price target from ...

expert-ratings-for-relay-therapeutics
Expert Ratings For Relay Therapeutics
08/07/2024 18:00:35

oppenheimer-maintains-outperform-on-relay-therapeutics-lowers-price-target-to-24
Oppenheimer Maintains Outperform on Relay ...
08/07/2024 11:52:53

Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price target...

relay-therapeutics-q2-2024-gaap-eps-069-beats-073-estimate
Relay Therapeutics Q2 2024 GAAP EPS $(0.69...
08/06/2024 20:56:14

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(...

barclays-maintains-overweight-on-relay-therapeutics-lowers-price-target-to-14
Barclays Maintains Overweight on Relay The...
07/26/2024 11:35:44

Barclays analyst Peter Lawson maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and lowers the price target from ...

jmp-securities-maintains-market-outperform-on-relay-therapeutics-lowers-price-target-to-21
JMP Securities Maintains Market Outperform...
07/18/2024 11:27:08

JMP Securities analyst Silvan Tuerkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and lowers the pr...

expert-ratings-for-relay-therapeutics
Expert Ratings For Relay Therapeutics
07/17/2024 12:01:40

hc-wainwright--co-maintains-buy-on-relay-therapeutics-lowers-price-target-to-18
HC Wainwright & Co. Maintains Buy on Relay...
07/17/2024 10:22:28

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price targ...

relay-therapeutics-receives-notice-of-termination-from-genentech-for-collaboration-and-license-agreement-relay-received-1218m-from-genentech-including-75m-upfront-and-45m-in-milestones
Relay Therapeutics Receives Notice Of Term...
07/16/2024 20:19:31

Effective In 180 Days; Agreement Involved Development Of Migoprotafib (GDC-1971); No Further Payments Or Obligations After Term...

expert-ratings-for-relay-therapeutics
Expert Ratings For Relay Therapeutics
06/07/2024 12:00:41

hc-wainwright--co-reiterates-buy-on-relay-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Rela...
06/07/2024 10:57:53

HC Wainwright & Co. analyst Robert Burns reiterates Relay Therapeutics (NASDAQ:RLAY) with a Buy and maintains $20 price ...

relay-therapeutics-cash-guidance-remains-unchanged-and-is-expected-to-fund-operations-into-2h-of-2026
Relay Therapeutics Cash Guidance Remains U...
06/06/2024 12:23:45

The new programs announced today do not change cash guidance, which is expected to fund operations into the second half of 2026.

relay-therapeutics-discloses-three-new-programs-including-2-genetic-disease-programs--1-precision-oncology-program
Relay Therapeutics Discloses Three New Pro...
06/06/2024 11:18:57

Core News & Articles
Relay Therapeutics And Pfizer Collaborate ...
06/05/2024 20:31:34

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by ...

key-takeaways-from-relay-therapeutics-analyst-ratings
Key Takeaways From Relay Therapeutics Anal...
05/10/2024 18:00:35

barclays-upgrades-relay-therapeutics-to-overweight-maintains-price-target-to-15
Barclays Upgrades Relay Therapeutics to Ov...
05/10/2024 13:22:39

Barclays analyst Peter Lawson upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and maintains the pr...

jmp-securities-reiterates-market-outperform-on-relay-therapeutics-maintains-24-price-target
JMP Securities Reiterates Market Outperfor...
05/06/2024 15:07:14

JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and maintains $2...

oppenheimer-reiterates-outperform-on-relay-therapeutics-lowers-price-target-to-25
Oppenheimer Reiterates Outperform on Relay...
05/06/2024 11:58:36

Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price targe...

relay-therapeutics-q1-2024-gaap-eps-062-beats-071-estimate-sales-10007m-beat-87500k-estimate
Relay Therapeutics Q1 2024 GAAP EPS $(0.62...
05/02/2024 21:52:54

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/10/2024 20:31:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION